Recombinant activated factor VII attenuates major arterial bleeding in noncoagulopathic rabbits

Background and objective Recombinant activated factor VII (rFVIIa), which is used off-label as an adjuvant therapy for uncontrolled and life-threatening bleeding, might also attenuate intractable bleeding related to macrovascular arterial lesions. Here we evaluated the efficacy of rFVIIa in sealing a large arterial wound in haemostatically competent rabbits. Methods Sixty male New Zealand rabbits were randomly divided into vehicle control and 80 and 200 μg kg−1 rFVIIa groups (n = 20 animals each). A standardized wound of the isolated right carotid artery was made in all rabbits with an 18-G catheter. Bleeding, which was limited by mild compression, was assessed every minute. At 5 min, an intravenous bolus of vehicle or human rFVIIa was given and the animals were further observed for 1 h. Efficacy was assessed from the bleeding duration and blood mass lost. Statistical significance was defined as P less than 0.05. All investigators were blinded to the treatment the animals received. Results The bleeding duration and blood mass lost were significantly reduced in both rFVIIa dosage groups as compared with the vehicle control group. For the vehicle, 80 and 200 μg kg−1 rFVIIa groups, the median bleeding durations were 56 min (range 7–60 min), 15 min (range 5–60 min) and 10 min (range 5–60 min), respectively; and the median blood mass losses were 22.5 g (range 1–58 g), 12 g (range 0–36 g) and 5 g (range 0–31 g), respectively. The prothrombin time was shorter in the rFVIIa groups. Visual inspection of the carotid artery and microscopic analysis of the liver and kidney revealed neither gross thrombi nor entrapped microthrombi in any rabbit. Conclusion Recombinant FVIIa at 80 or 200 μg kg−1 promoted the sealing of a large and slightly compressed arterial wound in rabbits. These results suggest a potential role for the drug in the management of massive bleeds due to an arterial lesion when surgical intervention is not immediately and readily available. Safety should remain a matter of concern.

[1]  U. Hedner Recombinant activated factor VII as a universal haemostatic agent. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[2]  R. Martineau,et al.  A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. , 2008, The New England journal of medicine.

[3]  Dougald M Monroe,et al.  The use of recombinant factor VIIa in the treatment of bleeding disorders. , 2004, Blood.

[4]  E. Kirkman,et al.  Recombinant activated factor VII increases survival time in a model of incompressible arterial hemorrhage in the anesthetized pig. , 2007, The Journal of trauma.

[5]  J. Vincent,et al.  Management of bleeding following major trauma: an updated European guideline , 2010, Critical care.

[6]  Kevin Fox,et al.  Experience-dependent plasticity mechanisms for neural rehabilitation in somatosensory cortex , 2009, Philosophical Transactions of the Royal Society B: Biological Sciences.

[7]  G. Gallioli,et al.  Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. , 1998, Intensive care medicine.

[8]  C. Samama,et al.  Modified Folts models in the rabbit: variations on a well worn theme. , 2009, European journal of anaesthesiology.

[9]  S. Bélisle,et al.  Efficacy and safety of recombinant activated factor VII to control bleeding in nonhemophiliac patients: a review of 17 randomized controlled trials. , 2008, The Annals of thoracic surgery.

[10]  R. Rossaint,et al.  Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. , 2005, The Journal of trauma.

[11]  I. C. Tudor,et al.  The risk associated with aprotinin in cardiac surgery. , 2006, The New England journal of medicine.

[12]  G. Gallioli,et al.  Antithrombin III (ATILL) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study , 1998, Intensive Care Medicine.

[13]  J. Holcomb,et al.  RECOMBINANT FACTOR VIIA REDUCES REBLEED HEMORRHAGE VOLUME IN A SWINE AORTOTOMY MODEL: A RANDOMIZED DOUBLE-BLINDED STUDY , 2007, Shock.

[14]  J. Stamler,et al.  Intravenous Nitroglycerin Infusion Inhibits Cyclic Blood Flow Responses Caused by Periodic Platelet Thrombus Formation in Stenosed Canine Coronary Arteries , 1991, Circulation.

[15]  Rolf Rossaint,et al.  Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective , 2006, Critical care.

[16]  S. Stanworth,et al.  Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. , 2007, The Cochrane database of systematic reviews.

[17]  S. Rapaport,et al.  Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. , 1990, Blood.

[18]  J. Holcomb,et al.  Preclinical trauma studies of recombinant factor VIIa , 2005, Critical care.

[19]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[20]  J. Folts An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. , 1991, Circulation.

[21]  M. Chiariello,et al.  Induction of Tissue Factor in the Arterial Wall During Recurrent Thrombus Formation , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[22]  E. Erhardtsen,et al.  A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects , 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[23]  F. Sellke,et al.  Safety and Efficacy of Recombinant Activated Factor VII: A Randomized Placebo-Controlled Trial in the Setting of Bleeding After Cardiac Surgery , 2009, Circulation.

[24]  A. Pusateri,et al.  Effect of haemodilution, acidosis, and hypothermia on the activity of recombinant factor VIIa (NovoSeven®) , 2008, British journal of anaesthesia.